DERM News & Events

Mega-caps helped power the S&P 500 index to fresh record highs as the Tech/AI-trade returned with a vengeance on Wednesday following Tuesday's stumble.  Alphabetand Nvidiaset record highs above $400 and $225 per share respectively while Micronrebounded by about 5%, erasing all of yesterday's losses, with Communication Services and Tech also joined by Consumer Cyclicals as the best three sectors in the benchmark thanks to the 2% bounce for Amazon2% and another 3% gain for Tesla.  Among the worst performing areas of the market were the Financials, where Regional Banking ETFsaw a decline of 1.6%.In the evening session, S&P e-minis are up a decimal while Nasdaq 100 contract is up 0.3% as the powerful Tech surge is showing no signs of letting up.  Afterhours earnings was highlighted by strong results from Cisco- the stock was up 18% after a Q3 earnings beat and guidance raise accompanied by a round of layoffs.  "Cisco delivered record quarterly revenue in Q3 and we saw very strong, broad-based demand for our products... (and the company) is well-positioned as the critical infrastructure for the AI era." said the company CEO.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Ciscoup 17.9%Grocery Outletup 17.2%STAAR Surgicalup 15.4%StubHub Holdingsup 12.6%Journey Medicalup 6.0%Jack in the Boxup 2.0%ALSO HIGHER -SharkNinjaup 5.6% after entering S&P MidCap 400 indexF&G Annuities & Lifeup 4.3% after entering S&P SmallCap 600 indexDOWN AFTER EARNINGS -Doximitydown 18.3%Enovixdown 11.3%ALSO LOWER -PDF Solutionsdown 8.9% after equity offeringKodiak Gas Servicesdown 4.9% after equity offering

Reports Q1 revenue $15.96M, consensus $15.48M. Claude Maraoui, Journey Medical's co-founder, president and CEO, said, "2026 is off to a strong start, as we delivered solid revenue growth and cash generation in the first quarter of the year. Prescription demand and payer coverage for Emrosi continue to increase, with the product's differentiated clinical profile gaining traction as we establish Emrosi as the best-in-class oral treatment for patients suffering from rosacea. Increasing refill rates and a growing number of Emrosi prescribers are also building momentum behind the brand. Our net product sales growth in the quarter coupled with disciplined investment in our dermatology-focused commercial infrastructure resulted in improved operating leverage, and we expect this trend to continue going forward. With over $27 million in cash and Emrosi(R) entering its second year on the market, we remain well-positioned to continue to execute on our strategy and deliver strong financial progress throughout the year."

Journey Medical announced that approximately 85% of all commercial lives in the United States now have access to Emrosi after contracting with the third major group purchasing organization, GPO. Emrosi is for the treatment of inflammatory lesions of rosacea in adults. Journey Medical continues to execute on the launch of Emrosi, with expanded payer access anticipated to facilitate further growth in total prescription demand.